Select Language
Free Registration
My Cart

SN38

SN38 Product List

  • Product Category

    Antibody (3)

  • Product Status

    Launched (3)

  • Species

    Mouse (3)

  • Tag

    - (3)

  • Conjugate

    Unconjugated (1)HRP Labeled (1)Biotin-labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
SN8-BVM808
Mouse
HEK293
Biotinylated Anti-SN38 Antibody, Mouse IgG1, Avitag™ Add to Cart
SN8-M685
Mouse
HEK293
Monoclonal Anti-SN38 Antibody, Mouse IgG1 Add to Cart
SN8-PLM685
Mouse
HEK293
HRP conjugated Monoclonal Anti-SN38 Antibody, Mouse IgG1 Add to Cart
Total: 3
  • 1

SN38 Background

Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A). Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BRwith IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL). HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
ALXN-2220ALXN2220; ALXN-2220; NI006; NI-006Phase 3 ClinicalAstraZeneca global R & D (China) Co LtdCardiomyopathies; Transthyretin amyloidosis
Details
Nexiguran ziclumeranNTLA-2001Phase 3 ClinicalIntellia Therapeutics IncAmyloidosis, Familial; Amyloid Neuropathies, Familial; Peripheral Nervous System Diseases; Metabolism, Inborn Errors; Polyneuropathies; Genetic Diseases, Inborn; Metabolic Diseases; Cardiomyopathies; Amyloidosis; Nervous System Diseases; Neuromuscular Diseases; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Amyloid Neuropathies; Transthyretin amyloidosis
Details
NNC6019-0001NNC6019-0001; NNC-6019; PRX-004Phase 2 ClinicalNovo Nordisk A/SCardiomyopathies; Transthyretin amyloidosis
Details
NI-006NI-006Phase 1 ClinicalNeurimmune AgCardiomyopathies; Transthyretin amyloidosis
Details
NucresiranALNTTRsc-04Phase 1 ClinicalAlnylam Pharmaceuticals IncTransthyretin amyloidosis
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
PatisiranSAR-438037; GENZ-438027; ALN-TTR02; ALN-18328ApprovedAlnylam Pharmaceuticals IncOnpattroUnited StatesAmyloid Neuropathies, FamilialAlnylam Pharmaceuticals Inc2018-08-10Amyloidosis, Familial; Amyloid Neuropathies, Familial; Polyneuropathies; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies
Details
VutrisiranALN-TTRSC02ApprovedAlnylam Pharmaceuticals IncAMVUTTRAUnited StatesAmyloid Neuropathies, Familial; Transthyretin amyloidosisAlnylam Pharmaceuticals Inc2022-06-13Amyloidosis, Familial; Amyloid Neuropathies, Familial; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis
Details
AcoramidisAG-10; ALXN-2060; ALXN 2060; BBP-265ApprovedStanford UniversityAttrubyUnited StatesTransthyretin amyloidosisBridgebio Pharma Inc2024-11-22Polyneuropathies; Heart Diseases; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies
Details
Inotersen sodiumISIS-420915; GSK-2998728ApprovedIonis Pharmaceuticals IncTegsediEUAmyloidosisAkcea Therapeutics Ireland Ltd2018-07-05Adenomatous Polyposis Coli; Amyloid Neuropathies, Familial; Amyloidosis; Transthyretin amyloidosis
Details
TafamidisPF-6291826; Fx-1006A; PF-06291826; FX-1006AApprovedPfizer Inc维万心, VYNDAMAXUnited StatesHeart DiseasesFoldrx Pharmaceuticals Inc2019-05-03Heart Diseases; Transthyretin amyloidosis
Details
EplontersenIONIS-TTR-LRx; AKCEA-TTR-LRx; ION-682884; ION-TTR-LRxApprovedIonis Pharmaceuticals IncWAINUAUnited StatesTransthyretin amyloidosisAstrazeneca Ab2023-12-21Amyloid Neuropathies, Familial; Cardiomyopathies; Transthyretin amyloidosis
Details
Tafamidis MeglumineFX-1006A; PF-6291826; Fx-1006A; PF-06291826ApprovedPfizer Inc维达全, VyndaqelEUAmyloidosisPfizer Europe Ma Eeig2011-11-16Amyloid Neuropathies, Familial; Immunoglobulin Light-chain Amyloidosis; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland